Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer

References

• MeyersonMGabrielSGetzGAdvances in understanding cancer genomes through second-generation sequencingNat Rev Genet2010111068569620847746
   PubMed Web of Science ®Google Scholar
• de BonoJSAshworthATranslating cancer research into targeted therapeuticsNature2010467731554354920882008
   PubMed Web of Science ®Google Scholar
• YapTASandhuSKWorkmanPde BonoJSEnvisioning the future of early anticancer drug developmentNat Rev Cancer201010751452320535131
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• SacherAGJännePAOxnardGRManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerCancer2014120152289229824752335
   PubMed Web of Science ®Google Scholar
• KatakamiNAtagiSGotoKLUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or bothJ Clin Oncol201331273335334123816963
   PubMed Web of Science ®Google Scholar
• YangJCHirshVSchulerMSymptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273342335023816967
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
• HirshVCadranelJCongXJSymptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1)J Thorac Oncol20138222923723328549
   PubMed Web of Science ®Google Scholar
• SchulerMHPlanchardDYangJCHInterim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapyPresented at: 2012 Annual Meeting of the American Society of Clinical Oncology2012Chicago, IL
   Google Scholar
• OxnardGRArcilaMEChmieleckiJLadanyiMMillerVAPaoWNew strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancerClin Cancer Res201117175530553721775534
   PubMed Web of Science ®Google Scholar
• PaoWChmieleckiJRational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNat Rev Cancer2010101176077420966921
   PubMed Web of Science ®Google Scholar
• ArcilaMEOxnardGRNafaKRebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayClin Cancer Res20111751169118021248300
   PubMed Web of Science ®Google Scholar
• YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med2008359436637718596266
   PubMed Web of Science ®Google Scholar
• JohnsonMLRielyGJRizviNAPhase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinibJ Thorac Oncol2011661128113121623279
   PubMed Web of Science ®Google Scholar
• SequistLVBesseBLynchTJNeratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerJ Clin Oncol201028183076308320479403
   PubMed Web of Science ®Google Scholar
• JanjigianYYAzzoliCGKrugLMPhase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinibClin Cancer Res20111782521252721248303
   PubMed Web of Science ®Google Scholar
• RielyGJKrisMGZhaoBProspective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusClin Cancer Res200713175150515517785570
   PubMed Web of Science ®Google Scholar
• CarpenterRLLoHWDacomitinib, an emerging HER-targeted therapy for non-small cell lung cancerJ Thorac Dis20124663964223205292
   PubMed Web of Science ®Google Scholar
• Pfizer IncPfizer announces top-line results from two phase 3 trials of dacomitinib in patients with refractory advanced non-small cell lung cancer Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_top_line_results_from_two_phase_3_trials_of_dacomitinib_in_patients_with_refractory_advanced_non_small_cell_lung_cancerAccessed: July 1, 2014
   Google Scholar
• EllisPMLiuGMillwardMNCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKIPresented at: 2014 Annual Meeting of the American Society of Clinical Oncology2014Chicago, IL
   Google Scholar
• SolcaFDahlGZoephelATarget binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blockerJ Pharmacol Exp Ther2012343234235022888144
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• YapTAVidalLAdamJPhase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsJ Clin Oncol201028253965397220679611
   PubMed Web of Science ®Google Scholar
• EskensFAMomCHPlantingASA phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursBr J Cancer2008981808518026190
   PubMed Web of Science ®Google Scholar
• YapTAPopatSThe role of afatinib in the management of non-small cell lung carcinomaExpert Opin Drug Metab Toxicol20139111529153923985030
   PubMed Web of Science ®Google Scholar
• YangJCShihJYSuWCAfatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialLancet Oncol201213553954822452895
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPLUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M) advanced adenocarcinoma of the lungPresented at: 2013 Annual Meeting of the American Society of Clinical Oncology2013Chicago, IL
   Google Scholar
• YangJCSequistLVSchulerMHOverall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT)Presented at: 2014 Annual Meeting of the American Society of Clinical Oncology2014Chicago, IL
   Google Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
• JackmanDPaoWRielyGJClinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerJ Clin Oncol201028235736019949011
   PubMed Web of Science ®Google Scholar
• SchulerMHYangCHParkKContinuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib – LUX-Lung 5 (LL5)Presented at: 2014 Annual Meeting of the American Society of Clinical Oncology2014Chicago, IL
   Google Scholar
• CrossDAAshtonSEGhiorghiuSAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerCancer Discov Epub632014
   Web of Science ®Google Scholar
• ChmieleckiJFooJOxnardGROptimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingSci Transl Med201139090ra59
   PubMed Web of Science ®Google Scholar
• KimYKoJCuiZThe EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitorMol Cancer Ther201211378479122228822
   PubMed Web of Science ®Google Scholar
• JanjigianYYGroenHJHornLActivity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinibPresented at: 2011 Annual Meeting of the American Society of Clinical Oncology2011Chicago, IL
   Google Scholar
• JannePARamalingamSSYangJCClinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC)Presented at: 2014 Annual Meeting of the American Society of Clinical Oncology2014Chicago, IL
   Google Scholar
• SequistLVSoriaJCGadgeelSMFirst-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)Presented at: 2014 Annual Meeting of the American Society of Clinical Oncology2014Chicago, IL
   Google Scholar
• KimDWLeeDHKangJHClinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs)Presented at: 2014 Annual Meeting of the American Society of Clinical Oncology2014Chicago, IL
   Google Scholar
• JanjigianYYSmitEFGroenHJDual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M MutationsCancer Discov Epub7292014
   Web of Science ®Google Scholar
• YeXZhuZZZhongLHigh T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?J Thorac Oncol2013891118112023945382
   PubMed Web of Science ®Google Scholar
• WalterAOSjinRTHaringsmaHJDiscovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCCancer Discov20133121404141524065731
   PubMed Web of Science ®Google Scholar
• CortotABRepellinCEShimamuraTResistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathwayCancer Res201373283484323172312
   PubMed Web of Science ®Google Scholar
• ErcanDXuCYanagitaMReactivation of ERK signaling causes resistance to EGFR kinase inhibitorsCancer Discov201221093494722961667
   PubMed Web of Science ®Google Scholar
• YapTALorenteDOmlinAOlmosDde BonoJSCirculating tumor cells: a multifunctional biomarkerClin Cancer Res201420102553256824831278
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar